Brief: Armata Pharmaceuticals Announces Completion Of Enrollment Of Phase 2 Tailwind Study Of Inhaled AP-PA02 In Non-Cystic Fibrosis Bronchiectasis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
11/07/2024 12:29
July 11 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT
OF
PHASE 2 TAILWIND STUDY OF INHALED AP-PA02 IN NON-CYSTIC FIBROSIS
BRONCHIECTASIS SUBJECTS WITH CHRONIC PULMONARY PSEUDOMONAS
AERUGINOSA INFECTION
* ARMATA PHARMACEUTICALS INC - PHASE 2 TOPLINE DATA
ANTICIPATED IN
2H 2024
* ARMATA PHARMACEUTICALS INC - LAST PATIENT FOLLOW-UP VISIT
SCHEDULED FOR AUGUST 7, 2024
* ARMATA PHARMACEUTICALS INC -PHASE 2 TOPLINE DATA
ANTICIPATED IN
2H 2024 FOLLOWED BY POTENTIAL INITIATION OF A PIVOTAL
BRONCHIECTASIS TRIAL IN 2025
Source text for Eikon: ID:nPn83mDWTa
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles